Sponsor Pipeline

Base Therapeutics (Shanghai) Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
3
Recruiting
8
Disease Areas
Active Trials by Phase
Early Phase 1
5
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Early Phase 1
NCT06541444 Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia Relapsed/Refractory Acute Myeloid Leukemia Recruiting
NCT07561437 NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors Advanced Solid Tumors Recruiting
NCT06097962 Safety and Efficacy of NK510 to Treat NSCLC NSCLC Recruiting
NCT07166263 Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer Gastric Cancer (GC) Not Yet Recruiting
NCT07657416 NK521 in the Treatment of Advanced Solid Tumors Hepatocellular Carcinoma (HCC) Not Yet Recruiting
Not specified
NCT07083349 NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus Refractory Systemic Lupus Erythematosus Not Yet Recruiting
Disease Areas
Get alerts when Base Therapeutics (Shanghai) Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free